Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc. is a pharmaceutical development company that focuses on repurposing approved active pharmaceutical ingredients to treat rare diseases, primarily targeting basal cell carcinoma nevus syndrome (Gorlin Syndrome). The company's lead development program centers on an oral formulation of itraconazole, an antifungal agent with anti-angiogenic properties that inhibit vascular growth supporting tumor proliferation. Its primary development candidate is a proprietary micronized and amorphous formulation developed to improve drug bioavailability and absorption for chronic disease management. The company currently operates without commercialized products, directing its activities toward preclinical and clinical evaluation to serve patients managed by dermatologists and Mohs micrographic surgeons.

The company operates primarily within the United States, targeting a domestic patient population of approximately 11,000 individuals with Gorlin Syndrome and an estimated prescriber base of 1,000 to 1,500 specialized Mohs surgeons. Inhibitor Therapeutics conducts its operations with two full-time employees and six part-time employees. It maintains its principal executive offices in Tampa, Florida.

Summary of the business section of Inhibitor Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of the date of this Report, we have two full-time employees and six part-time employees.”